Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements (e.g., insomnia and mood/behavior changes) are consistent with the label’s behavioral and CNS effects, but several specific details about timing, dose-dependence, duration of symptoms, and patient adjustment/mitigation are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Prednisone is a corticosteroid.
Warnings and Precautions / Behavioral and Mood Disturbances and elsewhere: label describes prednisone as a corticosteroid/adrenocortical steroid drug.
Prednisone can affect mood or energy levels.
5.5 Behavioral and Mood Disturbances: CNS effects including euphoria, mood swings, personality changes, severe depression, and psychotic manifestations.
Prednisone can cause trouble falling asleep.
5.5 Behavioral and Mood Disturbances: includes euphoria, insomnia, mood swings...
Prednisone can cause waking up during the night.
5.5 includes insomnia (label excerpt does not specify 'waking up during the night').
Prednisone can change normal sleep patterns.
5.5 includes insomnia (sleep disturbance) but does not explicitly mention sleep pattern changes.
Prednisone can cause difficulty sleeping.
5.5 Behavioral and Mood Disturbances: includes insomnia.
Prednisone can make people feel more 'wired' than usual.
5.5 Behavioral and Mood Disturbances: includes euphoria and CNS effects; label does not use the term 'wired'.
Unsupported Statements
Sleep disruption is more likely with higher doses of prednisone.
Provided label excerpts do not state dose-dependence for insomnia/sleep disruption.
Sleep disruption is more likely when prednisone is taken later in the day.
Provided label excerpts do not link time-of-day dosing with insomnia risk.
Taking prednisone earlier in the day, often in the morning, tends to reduce the chance of insomnia.
Provided label excerpts do not provide guidance that morning dosing reduces insomnia risk.
Sleep problems may improve after the body adjusts to prednisone.
Provided label excerpts do not mention adaptation/adjustment improving sleep problems.
Sleep problems may improve after the dose is lowered or stopped.
Provided label excerpts do not state that insomnia improves after dose reduction/cessation.
If prednisone is newly started, insomnia can be most noticeable in the first few days.
Provided label excerpts do not provide onset timing for insomnia after initiation.
Sleep problems may persist for more than about a week.
Provided label excerpts do not provide duration estimates for insomnia.
It can be dangerous to stop prednisone suddenly without medical guidance.
Provided label excerpts support gradual withdrawal rather than abrupt stopping (2.1), but the statement is framed generally as 'dangerous' to stop suddenly without medical guidance; label supports gradual tapering on discontinuation for long-term therapy, not a blanket prohibition.
Contradictions
Important Omissions
Dose/time-specific insomnia prevention guidance is not supported by the provided label excerpts (the response claims morning reduces insomnia and later dosing increases it).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
General statements about insomnia and mood effects are on-label, but the response adds specific dosing-time, dose-dependence, onset, and duration claims not supported by the provided label excerpts; the abrupt stopping claim is directionally consistent with gradual withdrawal language but is not precisely supported as written.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several sleep-related specifics (dose/time dependence and timing/duration of insomnia) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to on-label behavioral/CNS effects (insomnia and mood/behavior changes) and, for discontinuation, align wording with the label guidance: if stopping after long-term therapy, withdraw gradually rather than abruptly.